Drug intelligence / Profile preview

JNJ-61818549

Development stage: Unknown
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Intravenous

Overview

JNJ-61818549 is a small molecule drug developed by Janssen Global Services, a subsidiary of Johnson & Johnson. It has been investigated primarily as an intravenous microdose tracer in pharmacokinetic studies to assess the absolute bioavailability of other compounds, such as JNJ-42756493 (erdafitinib), rather than as a therapeutic agent itself. The compound does not have an established mechanism of action or primary disease indication for direct treatment use. Its main role has been in clinical research settings to support the development and characterization of other drugs[1][2].

Beyond the preview

Go deeper on JNJ-61818549.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-61818549.

Explore the full profile